Navigation Links
Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
Date:11/16/2011

elapsed/refractory AML that have an internal tandem duplication (ITD) mutation in the FLT3 gene.  Interim data from the first two patient cohorts demonstrated a composite complete response rate in 45 percent of patients, a median duration of response of 12.1 weeks, and survival of 24.7 weeks.  No treatment-related deaths have been reported.  The most common treatment-related adverse events included nausea, vomiting, fatigue and febrile neutropenia.  Several cases of QTc prolongation were reported in the study, but most resolved following a dose adjustment. AML is one of the most common types of blood cancers in adults, with ITD mutations in the FLT3 gene occurring in 25 percent to 30 percent of AML patients.  FLT3 ITD mutations confer poor prognosis, with early relapse and lower survival following treatment with existing therapies, including chemotherapy and hematopoietic stem cell transplant.

About Ambit Biosciences

Ambit Biosciences is a privately held biopharmaceutical company engaged in the development of a robust pipeline of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease and other indications.  Ambit's lead compound, quizartinib (AC220), is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML.  Ambit is developing quizartinib in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications.  In addition to quizartinib, Ambit's clinical pipeline includes AC430, an oral JAK2 inhibitor, and AC480, a pan-HER inhibitor.  Ambit also has a preclinical candidate, CEP-32496, a BRAF inhibitor licensed to Cephalon. For more information, visit www.ambitbio.com.

Media Contact:
'/>"/>

SOURCE Ambit Biosciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Ambit Biosciences Announces Transition in Company Leadership
2. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
3. Sangamo BioSciences Announces Presentation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
5. Neurocrine Biosciences Reports Third Quarter 2011 Results
6. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
7. GeneLink BioSciences, Inc. Ranked Number 33 Fastest Growing Company in North America on Deloittes 2011 Technology Fast 500™
8. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
9. Amarillo Biosciences Issues Corporate Update
10. Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference
11. Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 Follow us on ... revolutionize the world has attracted diverse players including ... start-ups. The early years of nanotechnology development was ... to the high risks involved, which deterred private ... this evolving technology have been growing over the ...
(Date:9/19/2014)... -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... to manufacture proteins including biosimilar therapeutics, today announced that ... Annual NewsMakers in the Biotech Industry conference in ... chief executive officer of Pfenex, will provide an overview ... Friday, September 26, 2014 at 10:00 a.m. EDT/7:00 a.m. ...
(Date:9/19/2014)... , September 19, 2014 ... Markets ( http://www.researchandmarkets.com/research/b2jxhs/micro_market ) has announced the addition of ... Columns"  report to their offering.       ... is one of the fastest-growing segments in the ... billion in 2013, and expected to reach $2.0 ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 ... urological and interventional radiology products and services, announced ... as cryotherapy and cryoablation) versus external beam radiotherapy ... of the American Urological Association (MAAUA) Annual Meeting ... "Comparing Relative Effectiveness of Cryosurgery and External Beam ...
Breaking Biology Technology:Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Pfenex to Present at Upcoming Industry Conference on September 26 2Micro Market Monitor : Global Pre-packed Chromatography Columns 2HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2
... Jan. 28 Ther-Rx Corporation, a,subsidiary of KV ... KV Pharmaceutical Company on January 26, 2009, a ... lots within,expiration) as a precautionary measure because they ... sufficiently comply with current Good,Manufacturing Practices (cGMPs). , ...
... Product is Japan,s first second-generation drug-eluting stentNATICK, Mass., ... BSX ) announced today that it has ... Labor and Welfare (MHLW) to market its TAXUS(R) ... plans to launch the product as soon as ...
... NOVATO, Calif., Jan. 28 BioMarin Pharmaceutical,Inc. (Nasdaq: ... BioMarin, will host a conference call and webcast on,Wednesday, February ... quarter,and full year 2008 financial results. , , ... International Dial-in Number: 617.213.8835, Participant ...
Cached Biology Technology:Ther-Rx Corporation Issues Nationwide Voluntary Recall of Products 2Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System 2Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System 3BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET) 2
(Date:9/19/2014)... Oklahoma biology professor will study the unique bioelectric signaling ... eventually benefit people,s health. The OU researcher is ... required to produce the signals used to map the ... at a rate of 500-600 discharges a second throughout ... electric fish are extreme, but necessary for survival. , ...
(Date:9/19/2014)... of fairness did not evolve for the sake of ... benefits of continued cooperation, so say Frans de Waal, ... article about inequity aversion (IA), which is defined as ... published in Science . , Their conclusion ... studies to address their hypothesis that it is the ...
(Date:9/19/2014)... 2014 Nxt-ID, Inc. (Nasdaq: NXTD and ... the growing m-commerce market, updates the "Wocket in Your Pocket" celebrity ... and light middleweight weight classes, Vinny Pazienza (PAZ). ... Game of Thrones actor Ciaran Hinds and ... star Katey Sagal have been cast in Bleed ...
Breaking Biology News(10 mins):Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3
... them get psyched up for contests, but when these ... gobble down before and during events, they could be ... treatments for the symptoms of an injury, not the ... University focuses on musculoskeletal health and sports medicine. "They ...
... A University of Maryland School of Medicine researcher will ... nation,s most prominent scientists in the field of stem ... and Preventive Medicine, was chosen by the National Heart, ... of this consortium of national experts, which will be ...
... , , ... Dec. 2 Communication Intelligence Corporation ("CIC") (OTC Bulletin ... for business process automation in the financial industry* and ... Systems Inc. ("Docubase"), a leading International Electronic Document Management ...
Cached Biology News:NSAIDs: Take 'em early and often when competing? Think again 2University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 2University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 3CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 2CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 3CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 4
Mouse monoclonal antibody raised against a partial recombinant FBXO11. NCBI Entrez Gene ID = FBXO11...
Mouse polyclonal antibody raised against a partial recombinant LASS3. NCBI Entrez Gene ID = 204219...
... Antibody against Nonmuscle Myosin II Heavy ... (Stored in TBS + 0.03% Thimerosal) ... peptide SDVNETQPPQSE corresponding to the C-terminus ... B (MHC-B) This antibody is effective ...
... Anti-Mi-2 Immunogen : ... acid residues 474-970 of human ... 7.4, 0.105M NaCl, 0.035% sodium ... Assurance: routinely evaluated by immunoblot ...
Biology Products: